To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
This is an open-label, multi-center clinical study to evaluate the efficacy and safety of XNW5004 tablets in subjects with R/R PTCL. The study plans to enroll approximately 50 subjects.
Relapsed/Refractory Peripheral T Cell Lymphoma
DRUG: XNW5004 tablets
Objective response rate (ORR) assessed by independent review committee (IRC), Percentage of participants achieving complete response (CR) and partial response (PR) in the study., 24 mounths
ORR assessed by investigator, Percentage of participants achieving complete response (CR) and partial response (PR)., 24 mounths|Progression free survival, time from the first dose of to the first disease progression(PD) or death, 24 mounths|Time to Response, time from the first dose of XNW5004 to first CR or PR, around 4 months|Duration of response, time from the first CR or PR to the first PD or death, 24 mounths|Overall survival, time from the fist dose of XNW5004 to death, around 5 years
This is an open-label, multi-center clinical study to evaluate the efficacy and safety of XNW5004 tablets in subjects with R/R PTCL. The study plans to enroll approximately 50 subjects.